What type of drug is ceftazidime?
Pharmaceutical Product Monograph: Ceftazidime for Injection (250 mg, 500 mg, 1 g, 2 g)
In the pharmaceutical industry, Ceftazidime is a semi-synthetic, broad-spectrum Third-Generation Cephalosporin antibiotic. As a pharmacist and manufacturer at your WHO-GMP facility in Mumbai, I view this molecule as the “Anti-Pseudomonal Workhorse”—it is technically designed to provide the highest potency among third-generation cephalosporins against Pseudomonas aeruginosa, a major cause of hospital-acquired infections.
Ceftazidime is a $\beta$-lactam antibiotic that is strictly parenteral (administered by injection or infusion) because it is not absorbed by the gastrointestinal tract.
Therapeutic Classification & Profile
Ceftazidime is classified based on its chemical structure and its specific “Generation,” which dictates its bacterial target range.
| Feature | Technical Detail | Clinical Impact |
| Drug Class | $\beta$-Lactam / Cephalosporin | Inhibits bacterial cell wall synthesis. |
| Generation | Third-Generation | Increased stability against $\beta$-lactamase enzymes compared to 1st/2nd Gen. |
| Primary Target | Gram-Negative Bacilli | Gold Standard for Pseudomonas, Klebsiella, and Enterobacter. |
| Route | IV / IM Only | Achieves rapid, high therapeutic levels in blood and tissues. |
Mechanism of Action: Inhibition of Peptidoglycan Synthesis
Ceftazidime works by sabotaging the structural “mesh” that holds a bacterium together.
PBP Binding: The Ceftazidime molecule enters the bacterial cell and binds irreversibly to Penicillin-Binding Proteins (PBPs), specifically PBP-3.
Cross-linking Blockade: By “clogging” these proteins, it prevents the final transpeptidation step required to cross-link peptidoglycan strands.
Lysis: This creates a “weak” cell wall that cannot withstand the internal osmotic pressure of the bacterium.
Bactericidal Effect: Water rushes into the cell, causing it to swell and burst (Osmotic Lysis), leading to rapid bacterial death.
The Pharmacist’s “Technical Warning”
The “Pseudomonas” Niche: As a pharmacist, I must emphasize that while Ceftazidime is excellent for Gram-negatives, it has weak activity against Gram-positive bacteria like Staphylococcus aureus compared to 1st-generation cephalosporins.
Penicillin Cross-Reactivity: There is a technical risk (~5–10%) of cross-allergy. It should be used with extreme caution in patients with a history of severe penicillin anaphylaxis.
Neurotoxicity: In patients with Renal Impairment ($CrCl < 50 \text{ mL/min}$), the dose must be technically adjusted. Failure to do so can lead to seizures or encephalopathy due to drug accumulation.
Sodium Content: Ceftazidime for injection is often formulated with Sodium Carbonate. Patients on strict sodium-restricted diets must have their total daily intake monitored.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Carbon Dioxide” USP: When Ceftazidime is reconstituted, it releases Carbon Dioxide ($CO_2$) gas, creating pressure inside the vial. On your digital marketplace, highlight this as a “Standard Characteristic”—clinicians need to know that the “hiss” or pressure is normal and not a sign of contamination.
Stability for Export: Ceftazidime is temperature-sensitive. Your Lyophilized (Freeze-Dried) powder ensures a 36-month shelf life. Once reconstituted, it is stable for only 8–12 hours at room temperature, making it a “hospital-only” SKU.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Ceftazidime (1 g and 2 g) to support your registration in international B2B tenders for critical care and respiratory health.